4//SEC Filing
ARCH Venture Fund VIII, L.P. 4
Accession 0001209191-20-051402
CIK 0001634379other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 11:07 AM ET
Size
34.3 KB
Accession
0001209191-20-051402
Insider Transaction Report
Form 4
Metacrine, Inc.MTCR
ARCH Venture Fund VIII, L.P.
10% Owner
Transactions
- Conversion
Series C Convertible Preferred Stock
2020-09-18−138,734→ 0 total(indirect: See footnote)→ Common Stock (138,734 underlying) - Conversion
Series C Convertible Preferred Stock
2020-09-18−138,734→ 0 total(indirect: See footnote)→ Common Stock (138,734 underlying) - Conversion
Common Stock
2020-09-18+472,251→ 2,433,035 total(indirect: See footnote) - Purchase
Common Stock
2020-09-18$13.00/sh+210,000$2,730,000→ 2,781,769 total(indirect: See footnote) - Purchase
Common Stock
2020-09-18$13.00/sh+20,000$260,000→ 158,734 total(indirect: See footnote) - Conversion
Common Stock
2020-09-18+1,960,784→ 1,960,784 total(indirect: See footnote) - Conversion
Common Stock
2020-09-18+138,734→ 2,571,769 total(indirect: See footnote) - Conversion
Common Stock
2020-09-18+138,734→ 138,734 total(indirect: See footnote) - Conversion
Series A Convertible Preferred Stock
2020-09-18−1,960,784→ 0 total(indirect: See footnote)→ Common Stock (1,960,784 underlying) - Conversion
Series B Convertible Preferred Stock
2020-09-18−472,251→ 0 total(indirect: See footnote)→ Common Stock (472,251 underlying)
Footnotes (3)
- [F1]Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- [F2]These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F3]These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Documents
Issuer
Metacrine, Inc.
CIK 0001634379
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001605598
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 11:07 AM ET
- Size
- 34.3 KB